3种银杏叶制剂治疗冠心病心绞痛的成本—效果分析  

Cost-effectiveness Analysis of 3 Ginkgo Preparations on Coronary Heart Disease with Angina Pectoris

作　　者：王红雁[1] 杨文波[1] 

机构地区：[1]延边大学附属医院药剂科,延吉市133000

出　　处：《中国药房》2011年第44期4182-4183,共2页China Pharmacy

摘　　要：目的:比较3种银杏叶制剂治疗冠心病心绞痛的成本-效果。方法:将103例符合诊断标准的冠心病心绞痛患者按照不同的用药方案分成A组(34例)、B组(35例)、C组(34例)。A、C组分别给予生产厂商及规格不同(2mL vs.5mL)的舒血宁注射液20mL、B组给予银杏达莫注射液20mL,3组均静脉滴注,qd,治疗14d后观察疗效,并进行成本-效果分析。结果:3组心绞痛改善总有效率分别为70.59%、91.43%、73.53%。成本分别为5207.86元、3575.46元、5065.06元,成本-效果比分别为7377.62、3910.60、6888.43。结论:与A、C组比较,B组治疗方案成本-效果比更优。OBJECTIVE： To evaluate the cost-effectiveness on 3 ginkgo preparations on coronary heart disease （CHD） with angina pectoris （AP）. METHODS： A total of 103 cases with the diagnosis standard of angina pectoris were ascribed to 2 mL ginkgo biloba extract for injection （group A, 34 cases）, dipyridamole for injection （group B, 35 cases） and 5 mL ginkgo biloba extract for injection （group C, 34 cases）, qd, iv.gtt. respectively. The curative effects were observed analyzed by cost-effectiveness method after 14 days. RESULTS： The effective rates of improving pectoris were 70.59%、91.43% and 73.53%, the cost for 3 groups were 5 207.86, 3 575.46 and 5 065.06 yuan, and the cost-effectiveness ratios were 7 377.62、3 910.60 and 6 888.43, respectively. CONCLUSION： Compared with groups A and C, group B is superior in terms of the cost-effectiveness ratios.

关 键 词：冠心病心绞痛 银杏叶制剂 银杏达莫 成本-效果分析 

分 类 号：R541.4[医药卫生—心血管疾病]